Published in Cancer Weekly, December 13th, 2005
According to recent research from Germany, "In-vitro synergy of treosulfan and gemcitabine has been observed in chemotherapy-resistant tumors. This trial investigated the efficacy of gemcitabine plus treosulfan in metastatic uveal melanoma."
"Patients received 1000 mg/m2 of gemcitabine and treosulfan at a dose of 2500 or 3000 mg/m2 in cohort 1 and 3500 or 4000 mg/m2 in cohort 2. Chemotherapy was administered on days 1 and 8 every 4 weeks. Thirty-three patients were treated, 14 in cohort 1 and 19 in cohort 2," explained A. Schmittel...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.